Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Strategy
MSTR
US Stock MarketDetailed Quotes
IMAB I-Mab
- 0.812
- -0.045-5.24%
Close Mar 10 16:00 ET
66.18MMarket Cap-0.85P/E (TTM)
0.860High0.810Low127.92KVolume0.860Open0.857Pre Close106.23KTurnover0.27%Turnover RatioLossP/E (Static)81.50MShares2.00052wk High0.30P/B38.98MFloat Cap0.76052wk Low--Dividend TTM48.01MShs Float85.400Historical High--Div YieldTTM5.84%Amplitude0.760Historical Low0.830Avg Price1Lot Size
I-Mab Stock Forum
The Phase 1b program consists of a dose escalation study (n=17) and a dose expansion study (n=40). Topline datafrom the dose escalation study is e...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
Wednesday, 8th January at 7:00 am
Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs)
ROCKVILLE, Md., Jan. 8, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment...
I-Mab Prioritizes Givastomig Cancer Drug Program, Reports $184M Cash Runway Through 2027
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
Monday, 6th January at 7:00 am
• Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization
• The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second hal...
ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18....
Benzinga· 1 min ago
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels.The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; giv...
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials
- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients
- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to ...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology (CLVS.US)$ +11.3%, $Cardiff Oncology (CRDF.US)$ +9%, $Immatics (IMTX.US)$ +8.3%, $IDEAYA Biosciences (IDYA.US)$ +8%, $Lyra Therapeutics (LYRA.US)$ +5.7%, $POINT Biopharma (PNT.US)$ +5.7%, $Edgewise Therapeutics (EWTX.US)$ +4.7%, $Concert Pharmaceuticals (CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals (DCPH.US)$ +3.2%, $Veracyte (VCYT.US)$ +2.6%, $SpringWorks Therapeutics (SWTX.US)$ +2.3%, ...
No comment yet